I'm referring to the announcement last August.
4 patients treated in a trial that ran for 2.5 years. Management kept being extremely coy about details of trial progress.
I suppose it was really 2 years, with the clinical trial website stating that the trial had ceased due to poor patient enrollment in Dec 2022. It just took management another 8 months to update shareholders.
That's definitely what I'd call a trial failure. Management, governance and communication failures also.
Ann: Positive Ph I/II DFI Efficacy Data to Support Site Expansion, page-24
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
48.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $111.1M | |||
| Open | High | Low | Value | Volume |
| 48.0¢ | 48.5¢ | 47.0¢ | $86.44K | 181.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 139334 | 47.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 48.5¢ | 20000 | 1 |
View Market Depth
| Last trade - 15.47pm 07/08/2024 (20 minute delay) ? |
| RCE (ASX) Chart |